Corbus CEO sells 17,000 shares under trading plan

Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported selling 17,000 shares of common stock on August 7, 2026 at a weighted average price of $10.0821 per share.

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported selling 17,000 shares of common stock on August 7, 2026 at a weighted average price of $10.0821 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Cohen holds 157,316 shares directly, including 138,049 unvested RSUs subject to vesting schedules.

Insider Trade Summary 10b5-1

Net Seller: 17,000 shares

Net Sell 1 txn

Insider Cohen Yuval

Role Chief Executive Officer

Sold 17,000 shs ($171K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share F1, F2, F3	17,000	$10.0821	$171K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 157,316 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported.

Key Figures

Shares sold: 17,000 shares Weighted average sale price: $10.0821 per share Post-transaction holdings: 157,316 shares +3 more

6 metrics

Shares sold 17,000 shares Common stock sale by Yuval Cohen on August 7, 2026

Weighted average sale price $10.0821 per share Price for 17,000 CRBP shares sold in multiple trades

Post-transaction holdings 157,316 shares Direct holdings of Yuval Cohen after the sale

Unvested RSUs included in holdings 138,049 RSUs Unvested restricted stock units subject to vesting schedules

10b5-1 plan adoption date March 11, 2026 Date Yuval Cohen adopted the Rule 10b5-1 trading plan

Sale price range $10.00 to $10.18 per share Range of prices for the multiple transactions comprising the sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, unvested RSUs, restricted stock units

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

unvested RSUs financial

"This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule"

restricted stock units financial

"unvested RSUs subject to each grant's vesting schedule as previously reported."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Corbus Pharmaceuticals (CRBP) report for Yuval Cohen?

Yuval Cohen, CEO of Corbus Pharmaceuticals (CRBP), reported selling 17,000 shares of common stock on August 7, 2026. The sale occurred at a weighted average price of $10.0821 per share in multiple trades between $10.00 and $10.18.

Was the CRBP insider sale by Yuval Cohen under a Rule 10b5-1 plan?

Yes. The sale by CRBP CEO Yuval Cohen was effected under a Rule 10b5-1 trading plan. The plan was adopted on March 11, 2026, indicating the trades were pre-arranged rather than discretionary at the time of execution.

How many CRBP shares did Yuval Cohen retain after the reported sale?

After selling 17,000 shares, CRBP CEO Yuval Cohen directly holds 157,316 shares of common stock. This total includes 138,049 unvested RSUs, which remain subject to their respective vesting schedules as previously reported.

What price range were the CRBP shares sold at by Yuval Cohen?

The 17,000 CRBP shares sold by Yuval Cohen were executed at prices ranging from $10.00 to $10.18 per share. The reported transaction price of $10.0821 is a weighted average across these multiple trades.

What role does Yuval Cohen hold at Corbus Pharmaceuticals (CRBP)?

Yuval Cohen serves as both a director and the Chief Executive Officer of Corbus Pharmaceuticals Holdings, Inc. His Form 4 filing reflects personal direct ownership and a pre-planned Rule 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 04:31 PM Accepted by SEC EDGAR 08/10/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Yuval

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/07/2026		S(1)		17,000	D	$10.0821(2)	157,316(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/Yuval Cohen	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)